Recent Updates
Recently added Catalysts
INDV Positive Sentiment Score: 70/100

Indivior To Participate In Upcoming Investor Conferences Indivior PLC (LSE: INDV) today announced that it will participate in the following investor events: Jefferies Healthcare Conference – New York City,...

Key Takeaway: Indivior PLC has announced its participation in notable upcoming investor conferences, including the Jefferies Healthcare Conference in New York City and the Stifel European Healthcare Conference in Bordeaux, France. CEO Mark Crossley and CFO Ryan Preblick will host meetings and presentations aimed at engaging with investors. The company emphasized its commitment to addressing substance use disorders and expanding its product pipeline. These events are part of Indivior's strategy to increase its visibility and reinforce its position in the pharmaceutical industry.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple high-profile investor conferences enhances visibility.
  • Leadership engagement through meetings and presentations indicates a proactive approach.
  • Focus on treating substance use disorders positions the company favorably within the healthcare sector.

Full Press Release Details

SLOUGH, England and RICHMOND, Va. , May 25, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced that it will participate in the following investor events:
Mark Crossley , Chief Executive Officer (CEO) and Ryan Preblick , Chief Financial Officer (CFO), will host 1x1/group meetings on Wednesday, June 7 th and host a presentation Wednesday June 7 th at 3:00 p.m. US EST. Investors can contact their Jefferies representative to schedule a meeting. The presentation will be available at www.indivior.com and can also be viewed using the following webcast link: https://wsw.com/webcast/jeff281/indv.l/2074930
Mark Crossley , CEO, will participate in the Stifel European Healthcare Conference in Bordeaux , France. Mr. Crossley will host 1x1/group meetings on Thursday, June 29 th and Friday, June 30 th . Investors can contact their Stifel representative to schedule a meeting.
About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA , Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 39 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .
SOURCE Indivior PLC

21 %

Frequently Asked Questions

When will Indivior host its investor presentation?

Indivior's investor presentation is scheduled for June 7 at 3:00 p.m. US EST.

Who will represent Indivior at the investor events?

Mark Crossley, CEO, and Ryan Preblick, CFO, will represent Indivior.

Where can I watch the Indivior presentation?

The presentation can be viewed at www.indivior.com or via a specific webcast link.

What is Indivior’s main focus as a pharmaceutical company?

Indivior focuses on developing medicines for substance use disorders and related mental illnesses.

In how many countries is Indivior's product portfolio available?

Indivior's products are available in 39 countries worldwide.

Last updated: May 25, 2023